Generalized anxiety disorder in medical practice

Primary Psychiatry

Volumn 12, Issue 3, 2005, Pages 30-34

  Hoehn Saric, Rudolf ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; BEHAVIOR; CARDIOVASCULAR SYMPTOM; CLINICAL FEATURE; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; GENETIC PREDISPOSITION; HUMAN; MUSCLE FUNCTION; NEUROBIOLOGY; ONSET AGE; PERSONALITY; PRIMARY MEDICAL CARE; SOMATIZATION; STRESS;

EID: 15744381914     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. First MB, Spitzer RL, Gibbon M, Williams J. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington, DC: American Psychiatric Press; 1997.
2. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
3. Hoehn-Saric R. Generalised anxiety disorder: guidelines for diagnosis and treatment. CNS Drugs. 1998;9(2):85-98.
4. Anderson DJ, Noyes R Jr, Crowe RR. A comparison of panic disorder and generalized anxiety disorder. Am J Psychiatry. 1984;141(4):572-575.
5. Weiner H. The psychobiology and pathophysiology of anxiety and fear. In: Tuma AH, Maser J, eds. Anxiety and the Anxiety Disorders. Hillsdale, NJ: Lawrence Erlbaum; 1985:333-345.
6. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed rev. Washington, DC: American Psychiatric Association; 1987.
7. International Statistical Classification of Diseases and Related Health Problems. 10th rev. Geneva, Switzerland: World Health Organization; 2003.
8. Noyes RJ, Hoehn-Saric R. The Anxiety Disorders. Cambridge, UK: Cambridge University Press; 1998.
9. Lader M. The nature of clinical anxiety in modern society. In: Spielberger CD, Sarason IG, eds. Stress and Anxiety. New York, NY: John Wiley & Sons; 1975:3-26.
10. Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 2001;62(suppl 11):53-58.
11. Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry. 2001;158(10):1568- 1578.
12. Noyes R Jr, Woodman C, Garvey MJ, et al. Generalized anxiety disorder vs. panic disorder. Distinguishing characteristics and patterns of comorbidity. J Nerv Ment Dis. 1992;180(6):369-379.
13. Nestadt G, Samuels J, Riddle MA, et al. The relationship between obsessive-compulsive disorder and anxiety and affective disorders: results from the Johns Hopkins OCD Family Study. Psychol Med. 2001;31(3):481-487.
14. Grados MA, Leung D, Ahmed K, Aneja A. Obsessive-compulsive disorder and generalized anxiety disorder: a common diagnostic dilemma. Primary Psychiatry. 2005;12(3):40-46.
15. Allgulander C, Bandelow B, Hollander E, et al, for the World Council of Anxiety. WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr. 2003;8(8 suppl 1):53-61.
16. Hettema JM, Prescott CA, Kendler KS. Genetic and environmental sources of covariation between generalized anxiety disorder and neuroticism. Am J Psychiatry. 2004;161(9):1581-1587.
17. Akiskal HS. Anxiety: definition, relationship to depression, and proposal for an integrative model. In: Tuma AH, Maser JD, eds. Anxiety and the Anxiety Disorders. Hillsdale, NJ: Lawrence Erlbaum; 1985:787-797.
18. Bienvenu OJ, Brandes M. The interface of personality traits and anxiety disorders. Primary Psychiatry. 2005;12(3):35-39.
19. Hoehn-Saric R, Hazlett RL, McLeod DR. Generalized anxiety disorder with early and late onset of anxiety symptoms. Compr Psychiatry. 1993;34(5):291-298.
20. Davis M. The role of the amygdala in fear-potentiated startle: implications for animal models of anxiety. Trends Pharmacol Sci. 1992;13(1):35-41.
21. LeDoux JE. Emotional memory systems in the brain. Behav Brain Res. 1993;58(1-2):69-79.
22. Davis M. Are different parts of the extended amygdala involved in fear versus anxiety? Biol Psychiatry. 1998;44(12):1239-1247.
23. Gur RC, Gur RE, Resnick SM, Skolnick BE, Alavi A, Reivich M. The effect of anxiety on cortical cerebral blood flow and metabolism. J Cereb Blood Flow Metab. 1987;7(2):173-177.
24. Hoehn-Saric R, Schlund MW. Neural correlates of worry in generalized anxiety disorder: an fMRI study comparing patients with non-anxious volunteers [abstract]. Biol Psychiatry. 2003;53(suppl 8):8S.
25. Hoehn-Saric R, Schlund MW, Wong SH. Effects of citalopram on worry and brain activation in patients with generalized anxiety disorder. Psychiatry Res. 2004;131(1):11-21.
26. Charney DS. Psychobiological mechanisms of resilience and vulnerability: implications for successful adaptation to extreme stress. Am J Psychiatry. 2004;161(2):195-216.
27. Kent JM, Mathew SJ, Gorman JM. Molecular targets in the treatment of anxiety. Biol Psychiatry. 2002;52(10):1008-1030.
28. Hoehn-Saric R. Comparison of generalized anxiety disorder with panic disorder patients. Psychopharmacol Bull. 1982;18(4):104-108.
29. Logue MB, Thomas AM, Barbee JG, et al. Generalized anxiety disorder patients seek evaluation for cardiological symptoms at the same frequency as patients with panic disorder. J Psychiatr Res. 1993;27(1):55-59.
30. McLeod DR, Hoehn-Saric R. Perception of physiological changes in normal and pathological anxiety. In: Hoehn-Saric R, McLeod DR, eds. Biology of Anxiety Disorders. Washington, DC: American Psychiatric Press; 1993:223-243.
31. McLeod DR, Hoehn-Saric R, Zimmerli WD, De Souza EB, Oliver LK. Treatment effects of alprazolam and imipramine: physiological versus subjective changes in patients with generalized anxiety disorder. Biol Psychiatry. 1990;28(10):849-861.
32. Hoehn-Saric R, McLeod DR, Zimmerli WD. Somatic manifestations in women with generalized anxiety disorder: psychophysiological responses to psychological stress. Arch Gen Psychiatry. 1989;46(12):1113-1119.
33. Hoehn-Saric R, Hazlett RL, Pourmotabbed T, McLeod DR. Does muscle tension reflect arousal? Relationship between electromyographic and electroencephalographic recordings. Psychiatry Res. 1997;71(1):49-55.
34. Hoehn-Saric R, McLeod DR, Zimmerli WD. Symptoms and treatment responses of generalized anxiety disorder patients with high versus low levels of cardiovascular complaints. Am J Psychiatry. 1989;146(7):854-859.
35. Herd JA. Cardiovascular response to stress. Physiol Rev. 1991;71(1):305-330.
36. Blanchard EB, Scharff L, Schwarz SP, Suls JM, Barlow DH. The role of anxiety and depression in the irritable bowel syndrome. Behav Res Ther. 1990;28(5):401-405.
37. Hoehn-Saric R, McLeod DR, Funderburk F, Kowalski P. Somatic symptoms and physiologic responses in generalized anxiety disorder and panic disorder: an ambulatory monitor study. Arch Gen Psychiatry. 2004;61(9):913-921.
38. Davidson JR. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry. 2001;62(suppl 11):46-50.
39. McCann UD, Fauerbach JA, Thombs BD. Anxiety and cardiac disease. Primary Psychiatry. 2005;12(3):47-50.
40. McLeod DR, Hoehn-Saric R, Foster GV, Hipsley PA. The influence of premenstrual syndrome on ratings of anxiety in women with generalized anxiety disorder. Acta Psychiatr Scand. 1993;88(4):248-251.
41. Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety. 2002;16(4):162-171.
42. Wittchen HU, Kessler RC, Beesdo K, Krause P, Hofler M, Hoyer J. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry. 2002;63(suppl 8):24-34.
43. Souetre E, Lozet H, Cimarosti I, et al. Cost of anxiety disorders: impact of comorbidity. J Psychosom Res. 1994;38(suppl 1):151-160.
44. Liberman BL. The role of mastery in psychotherapy: maintenance of improvement and prescriptive change. In: Frank JD, Hoehn-Saric R, Imber SD, Liberman BL, Stone AR, eds. Effective Ingredients of Successful Psychotherapy. New York, NY: Brunner Mazel; 1978:35-72.
45. Borkovec TD, Whisman MA. Psychosocial treatment for generalized anxiety disorder. In: Mavissakalian M, Prien RF, eds. Long-Term Treatment for the Anxiety Disorders. Washington, DC: American Psychiatric Press; 1996:201-219.
46. McLeod DR, Hoehn-Saric R, Porges SW, Kowalski PA, Clark CM. Therapeutic effects of imipramine are counteracted by its metabolite, desipramine, in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2000;20(6):615-621.